Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Expert Opinion on Biological Therapy|September 15, 2021
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from ItalyMichele Francesco Chiappetta, Anna Viola, Mauro Mastronardi, et al.
Gastroenterology|April 9, 2013
Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistanceJavier Molina-Infante, Marco Romano, Miguel Fernandez-Bermejo, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 25, 2023
Lower urinary tract symptoms in patients with inflammatory bowel diseases: A cross-sectional observational studyLorenzo Romano, Raffaele Pellegrino, Davide Arcaniolo, et al.
Helicobacter|April 22, 2020
Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life studyMarco Romano, Antonietta Gerarda Gravina, Gerardo Nardone, et al.
Andrology|November 4, 2024
Sexual dysfunctions in inflammatory bowel disease: role of Mediterranean diet and quality of lifeLorenzo Romano, Mariano Fonticelli, Agnese Miranda, et al.
Frontiers in Medicine|December 26, 2022
A multicenter randomized phase 4 trial comparing sodium picosulphate plus magnesium citrate vs. polyethylene glycol plus ascorbic acid for bowel preparation before colonoscopy. The PRECOL trialValentina D'Angelo, Maria Carmela Piccirillo, Massimo Di Maio, et al.
The American Journal of Gastroenterology|April 25, 2022
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha InhibitorsSara Onali, Daniela Pugliese, Flavio Andrea Caprioli, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 3, 2014
Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatmentsJavier P Gisbert, Marco Romano, Javier Molina-Infante, et al.
Digestive Diseases and Sciences|November 14, 2019
Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative ColitisFabrizio Bossa, Giuseppe Biscaglia, Maria Rosa Valvano, et al.
United European Gastroenterology Journal|October 19, 2020
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of careSimone Saibeni, Ludovica Scucchi, Gabriele Dragoni, et al.
Pageof 4